The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
Bernard Zinman - One of the best experts on this subject based on the ideXlab platform.
-
sodium glucose co transporter inhibitors their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis the stop dka protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
-
Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:: Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
Ronald Goldenberg - One of the best experts on this subject based on the ideXlab platform.
-
sodium glucose co transporter inhibitors their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis the stop dka protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
-
Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:: Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
Jeremy Gilbert - One of the best experts on this subject based on the ideXlab platform.
-
sodium glucose co transporter inhibitors their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis the stop dka protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
-
Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:: Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
Irene Hramiak - One of the best experts on this subject based on the ideXlab platform.
-
sodium glucose co transporter inhibitors their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis the stop dka protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
-
Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a Risk Mitigation Strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Ronald Goldenberg, Jeremy Gilbert, Irene Hramiak, Bernard ZinmanAbstract:: Recent phase 3 clinical trials have evaluated the impact of adding sodium-glucose co-transporter (SGLT) inhibitors to the type 1 diabetes armamentarium. These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes. Diabetic ketoacidosis (DKA) is a feature of type 1 diabetes and the Risk is increased when SGLT inhibitors are used in type 1 diabetes. To minimize the Risk of DKA and still gain the multiple benefits, we developed the "STOP DKA Protocol ", an easily accessible and practical tool, that provides a Risk Mitigation Strategy for reducing DKA in patients with type 1 diabetes being treated with SGLT inhibitors.
Marc Rendell - One of the best experts on this subject based on the ideXlab platform.
-
commentary sglt inhibitors in type 1 diabetes place in therapy and a Risk Mitigation Strategy for preventing diabetic ketoacidosis the stop dka protocol
Diabetes Obesity and Metabolism, 2019Co-Authors: Marc RendellAbstract:: In the accompanying article, Goldenberg et al. review the promotion of diabetic ketoacidosis by SGLT2 inihibitors. They have carried out a metanalysis showing a 3.5-fold increase in the Risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes under treatment with SGLT2 inhibitors. They make a number of suggestions for attempting to mitigate the Risk of DKA in these patients, notably including blood ketone monitoring and the use of supplemental carbohydrates with additional insulin when ketones suggest incipient DKA. Their proposal merits evaluation in a clinical trial involving type 1 diabetes, which should also assess the possible cardiorenal benefits demonstrated with treatment with SGLT2 inhibitors in type 2 diabetes.
